Would You Even Know?
At Single Point of Contact, we’ve worked with early-stage biotech firms that believed their security stack was “covered.” Firewalls? Check. Endpoint protection? Installed. Cloud backups? Running.
But when we ask one simple question, the room goes quiet:
“If someone exfiltrated your research tonight, how would you know?”
For most pre-seed biotech firms, the honest answer is:
We wouldn’t.
And that’s the risk.
Tools Are Not Detection
You likely have:
- Endpoint protection (EDR)
- Microsoft 365 security alerts
- Cloud access logs
- Firewall notifications
- Basic MFA enabled
What you probably don’t have:
- Correlation between those logs
- 24/7 review of suspicious patterns
- Behavioral anomaly detection
- Alert triage and investigation workflows
- Someone accountable for reviewing security signals around the clock
Detection isn’t about collecting logs. It’s about connecting them. Its about interpretation of legit threats or an innocent download.
A compromised lab laptop downloading unusual datasets at 2 a.m. may generate a log entry.
But unless someone confirms that:
- Unusual VPN behavior
- Abnormal cloud storage uploads
- Credential misuse
- Failed authentication attempts
…it’s just noise in a dashboard no one checks.
Why Pre-Seed Biotech Is a Prime Target
You are in the most vulnerable stage of valuation.
Your firm likely holds:
- Proprietary formulas
- Pre-clinical research
- Trial datasets
- Patent-pending compounds
- Patient data subject to HIPAA
Yet you probably operate with:
- No full-time security analyst
- A small IT vendor
- No dedicated SOC
- No incident response playbooks
- No compliance validation for FDA 21 CFR Part 11
Attackers know this. They don’t attack the largest pharma first. They attack the smallest labs with the highest upside and lowest visibility. Cyber criminals are aware you have limited IT and security resources.
Signs You’re Already Missing
Here’s what CEOs should ask immediately:
- Do we review endpoint alerts daily?
- Who correlates firewall logs with cloud access logs?
- If an employee exports 30GB of data at midnight, who investigates?
- How quickly are suspicious alerts triaged?
- Do we have tamper-proof logging?
- Are failed login patterns reviewed across systems?
- Can we detect lateral movement between lab systems?
- Is anyone actively threat hunting?
If you hesitate on more than three of these, detection gaps exist.
And detection gaps are not theoretical.
Enzo Biochem Breach
Enzo Biochem suffered a ransomware breach that exposed patient data and disrupted operations. The cost wasn’t just financial. It included operational shutdowns, regulatory scrutiny, and reputational damage.
The lesson?
The breach did not begin with an explosion. It began quietly.
Almost all major biotech breaches start with:
- Credential compromise
- Phishing
- Remote access abuse
- Unmonitored endpoint behavior
And in early-stage firms, those early signals often go unnoticed.
FDA and HIPAA Exposure
For pre-seed biotech CEOs, breach detection isn’t just about data loss.
It’s about regulatory liability.
FDA 21 CFR Part 11 requires:
- Audit trails
- System validation
- Electronic record integrity
- Access controls
- Accountability for data changes
HIPAA requires:
- Continuous monitoring safeguards
- Access control enforcement
- Incident detection capability
- Documented response procedures
If a breach occurs and you cannot demonstrate monitoring discipline, regulators will ask:
“How were you supervising system integrity?” Silence is not an acceptable answer.
The Real Gap: Correlation
Most early-stage biotech firms have logs.
They do not have correlation.
Correlation means:
- Endpoint alerts are tied to user identity
- Cloud access patterns are analyzed against device behavior
- VPN access is evaluated against data transfer spikes
- Anomalies are reviewed within minutes, not weeks
Without correlation, detection is passive. And passive security is invisible failure.
What Proper Detection Looks Like
At minimum, CEOs should expect:
- 24/7 monitoring of endpoints, cloud, and firewall activity
- Centralized log aggregation (SIEM)
- Behavioral anomaly detection
- Rapid triage workflows
- Defined escalation protocols
- Incident response readiness
- Quarterly reporting to leadership
If you don’t have those, you do not have breach visibility. You have hope.
And hope is not a security strategy.
Final Thought
If someone accessed your IP right now, could you detect it within 15 minutes?
Or would you find out months later when valuation discussions stall and forensic investigators uncover quiet data exfiltration?
Early-stage biotech firms don’t collapse because of a single breach. They collapse because they never knew it was happening.
If this blog made you uncomfortable, that’s good.
At Single Point of Contact, we specialize in building 24/7 correlated detection environments for biotech firms that are too innovative to operate blind. If you’re unsure whether your current systems would alert you in time, book a consultation. Let’s evaluate it before someone else does.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
